Royalty Report: Cancer, Drugs, Diagnostic – Collection: 3479

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Cancer
  • Drugs
  • Diagnostic
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Biotechnology
  • Antibody
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3479

License Grant
The Licensor grants the Licensee a world-wide exclusive license to materials and methods for use in the diagnosis and treatment of metastatic spread of solid tumor cancers.
License Property
Licensors have developed certain hybridoma cell lines that produce and uses thereof in diagnosis, prognosis and treatment of tumors.

U.S. Provisional Patent Application No. 61/276,263, entitled 'Tumor Microenvironment of Metastasis (TMEM)

Cell Line means a hybridoma cell line that produces Anti-pan Mena murine monoclonal antibodies.

Materials means anti-pan Mena murine monoclonal antibodies produced by the Cell Line.

Diagnostic Field means products and services for diagnostic use.
Therapeutic Field means products and services for therapeutic use.

U.S. Patent Application No. 12/462,324, entitled 'Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors'

U.S. Continuation-in-part of PCT/US08/1343, entitled 'Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors'

In return, the Licensee has agreed to grant equity to Licensors, to reimburse Licensors patent expenses thus far incurred, to pay all future patent expenses, pay a royalty on any sales of product using Licensed technology, as well as certain minimum royalties and milestone payments.

Field of Use
The Licensee was formed to allow cancer patients to benefit from the latest discoveries in how cancer spreads to other organs in the body. The Licensee's goal is to become an industry leader in the emerging field of personalized cancer therapy.

IPSCIO Record ID: 369295

License Grant
Licensors, two Universities, hereby grant to Licensee and Affiliates (a) a worldwide, exclusive license to use (but not to sell or transfer) the Cell Line to make Materials for use in connection with Licensed Products; (b) a worldwide, exclusive license to make, use, offer to sell and sell Materials in connection with Licensed Products; and (c) a worldwide, exclusive license to Licensors’ rights in the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, provide, import, have imported, offer to sell, sell and have sold Licensed Products. Licensee will not grant any sublicense (or amend any sublicense) under Agreement Patents unless it first submits a full and complete draft of any such proposed sublicense (or amendment) to Licensors and then receives the prior written consent of Licensors.  Licensee shall provide Licensors with a full and complete copy of any approved sublicense (or amendment) within thirty (30) days of execution thereof by Licensee. The terms of any sublicense agreement shall be consistent with the terms of this Agreement and shall include (at least) the following provisions prohibiting any use of Licensors’ names, requiring indemnification of Licensors.
License Property
1. U.S. Provisional Patent Application No. 61/276,263, entitled “Tumor Microenvironment of Metastasis (TMEM) and Uses Thereof in Diagnosis, Prognosis, and Treatment of Tumors”, inventors Frank Gertler, John Condeelis, Thomas Rohan, and Joan Jones; assigned to MIT, Cornell (D-4846) and Einstein (96700/1532);

2. U.S. Continuation-in-part of PCT/US08/1343, entitled “Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors”, inventors John Condeelis, Sumanta Goswami, Paola Nistico, and Frank Gertler; assigned to Einstein, IFO and MIT (96700/1343);

3. U.S. Patent Application No. 12/462,324, entitled “Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors”, inventors John Condeelis, Sumanta Goswami, Paola Nistico, and Frank Gertler; assigned to Einstein, IFO and MIT (96700/1533)

Cell Line means a hybridoma cell line that produces Anti-pan Mena murine monoclonal antibodies.

Materials means Anti-pan Mena murine monoclonal antibodies produced by the Cell Line.

Field of Use
Field of use is for uses thereof in diagnosis, prognosis and treatment of tumors.

The License Agreement covers pending patent applications, patent disclosures, cell lines and technology surrounding discoveries in the understanding of the underlying mechanisms of metastasis in solid tumor epithelial cancers.

IPSCIO Record ID: 4557

License Grant
The Licensor hereby grants the Licensee a royalty-bearing license under the rights in the Tangible Property to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field in the Territory and to perform Licensed Services in the Field in the Territory.

Licensee shall have the right to grant a Sublicense to the Tangible Property.

License Property
United States of America Patent No. 8603738.
Field of Use
Field shall mean products and services for diagnostic use in humans.

The Licensee develops and commercializes novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.

IPSCIO Record ID: 328128

License Grant
The University grants an exclusive license to their rights in the patent rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field in the Territory and to develop and perform Licensed Processes solely to the extent necessary to develop Licensed Products and Identified Products in the Field in the Territory.
License Property
The Licensors are owners of patent rights for Alternatively Spliced mRNA Isoforms as Prognostic and Therapeutic Tools for Metastatic Breast Cancer and Other Invasive/Metastatic Cancers, and,  Alternatively Spliced mRNA Isoforms As Prognostic Indicators For Metastatic Cancer.
Field of Use
Patents and technology surround the discoveries of alternatively spliced mRNA and protein isoform markers for the diagnosis and prognosis of cancer through the epithelial to mesenchymal transition (“EMT”) in epithelial solid tumor cancers.

Field shall mean use or intended for use in the diagnosis and/or prognosis of cancer, and/or for the medical management of cancer, including without limitation the determination (whether by selection or exclusion) of a particular intervention for the prevention and/or treatment of cancer, in humans, including without limitation the use of specific reagents, kits or diagnostic devices.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 4234

License Grant
The University grants to the Canadian Licensee and exclusive, worldwide, perpetual right and license to use and practice, to make and have made, to use and have used, to offer for sale or lease, to sell or lease, have sold or leased, under the Patent Rights, the Technologies in the field of use.
License Property
The Licensor has developed and is the owner of all rights, title and interest to any technology or discovery, by assignment of certain Patent Rights incorporating Research Foundation Invention Case Number R1495-100, entitled Human Transcobalamin Receptor as a Target in Cancer Therapy.

Patent Rights
Application               Office                                                                         Serial No.
Provisional               US Patent and Trademark Office                       60/790,330
PCT                             World Intellectual Property Office                    PCT/US2007/008674
U.S.                            US Patent and Trademark Office                       12/296,254

Specifically the licensing rights relate to the group of patents relating to the Licensee's Research and Development strategy of developing monoclonal antibodies to the vitamin B12 receptor as specific delivery vehicles for cytotoxic payloads.

The Licensee has been successful in developing a specific murine monoclonal antibody to the transcobalamin receptor.  The antibody identified as mAbTCR23, has been demonstrated to be highly effective in targeting cancer cells and in inhibiting cell proliferation in a number of cell lines including solid tumors and lymphnoid malignancies.  The conjugation of the mAbTCR23 antibody to saporin, a highly effective intercellular cytotoxic agent, did not affect the biological activity of the antibody.

Field of Use
The Field of Use of the Technologies shall be all fields of use, including but not limited to diagnostic uses, and prophylactic and therapeutic treatment of human diseases, including but not limited to cancer.

IPSCIO Record ID: 328124

License Grant
The University grants a worldwide, exclusive license to Licensor’s rights in the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, provide, import, have imported, offer to sell, sell and have sold Licensed Products.
License Property
Licensor is the owner of a patent application related to isolation, gene expression, and chemotherapeutic resistance of motile cancer cells and human invasion signature for prognosis of metastatic risk.

The patents include Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells, and, Human Invasion Signature For Prognosis Of Metastatic Risk.

The intellectual property covered by the Second License Agreement are summarized as follows

1.
U.S. Patent Application No. 11/659,514 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

2.
Canadian Patent Application No. 2,576,702 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

3.
European Patent Application No. 05807467.5 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells”

4.
U.S. Provisional Patent Application (pending) entitled “Human Invasion Signature For Prognosis Of Metastatic Risk”

The intellectual property covered by the Third License Agreement are summarized as follows

1.
U.S. Patent Application No. 12/998,237 (based on PCT International Patent Application No. PCT/2009/005851) entitled “An In Vivo Quantitative Screening Test For Anti-Metastasis Treatment Efficacy”

Field of Use
The Diagnostic Field means products and services for diagnostic use.

The Therapeutic Field means products and services for therapeutic use.

IPSCIO Record ID: 830

License Grant
The Licensor hereby grants the Israeli Licensee within the Licensed Field an exclusive, worldwide, transferable, royalty-bearing license to conduct (whether directly or indirectly) research, development, and commercialization efforts relating to (a) the use of MabCure Hybridomas solely in relation to the production of Licensed Products.
License Property
The Licensor is the owner of certain assets and all intellectual rights in and to (a) certain hybridoma clones producing antibodies against prostate cancer (the MabCure Hybridomas), and (b) certain developed anti-PROSCA monoclonal antibodies against prostate cancer (the Licensed Products, and together with the MabCure Hybridomas, the Technology).
Field of Use
The technology includes hybridoma clones producing antibodies against prostate cancer and certain Licensor developed anti-PROSCA monoclonal antibodies against prostate cancer to conduct research, development, and commercialization efforts in the field of diagnosis, imaging, and therapy of prostate cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.